Literature DB >> 16365743

[Preoperative radiochemotherapy of advanced resectable cancer of the oral cavity with cisplatin vs paclitaxel/carboplatin. Analysis of two multimodality treatment concepts].

A Eckardt1, G Wegener, J H Karstens.   

Abstract

PURPOSE: The purpose of simultaneous chemoradiotherapy is to increase local tumor control and to decrease the incidence of distant metastases. Platinum-based chemotherapy regimens are widely accepted as standard treatment in advanced head and neck cancer. Due to their remarkable activity as well as radiosensitizing effects, taxanes play in increasing role in multimodality treatment concepts of solid tumors.
MATERIAL AND METHODS: Since 1989 a total of 85 patients with advanced squamous cell carcinoma of the oral cavity and oropharynx were recruited to participate in two different prospective clinical trials of preoperative chemoradiation. Both treatment concepts (study A: cisplatin 12.5 mg/m(2) plus radiation 36 Gy vs study B: Taxol 40 mg/m(2)/carboplatin AUC 1.5 plus radiation 40 Gy) were compared and further statistical analysis including descriptive analysis as well as univariate and multivariate analysis was performed.
RESULTS: At the time of the analysis a total of 47 patients (55.3%) were alive, 38 patients (44.7%) died from tumor-related causes. The overall survival for both patient groups at 5 years was 45.1% (study A) and 84.9% (study B) and after 10 years 32.4% for study group A. A comparative analysis of both groups revealed a highly significant survival benefit at 4 years for study B (p=0.0015). In various calculation models of the multivariate analysis the regimen containing Taxol/carboplatin (study B) was superior to the cisplatin regimen (study A).
CONCLUSION: Based on a retrospective analysis of two different concepts of preoperative chemoradiation and supported by recent data from the literature it is justified to conclude that taxane-based combination regimens are more effective compared to cisplatin-based regimens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16365743     DOI: 10.1007/s10006-005-0659-8

Source DB:  PubMed          Journal:  Mund Kiefer Gesichtschir        ISSN: 1432-9417


  20 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Authors:  Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

3.  Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.

Authors:  M Suntharalingam; M L Haas; D A Van Echo; R Haddad; M C Jacobs; S Levy; W C Gray; R A Ord; B A Conley
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

4.  Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results.

Authors:  T Kirita; K Ohgi; H Shimooka; Y Yamanaka; S Tatebayashi; K Yamamoto; K Mishima; M Sugimura
Journal:  Oral Oncol       Date:  1999-11       Impact factor: 5.337

5.  [Preclinical and clinical results in the simultaneous radiochemotherapy of head and neck tumors with Paclitaxel].

Authors:  W Hoffmann; V Heinrich; C Belka; W Budach; H Schmidberger; H Bochtler; H P Rodemann; M Bamberg
Journal:  Strahlenther Onkol       Date:  1996-05       Impact factor: 3.621

6.  Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer.

Authors:  J B Sunwoo; L L Herscher; G S Kroog; G R Thomas; F G Ondrey; D C Duffey; B I Solomon; C Boss; P S Albert; L McCullugh; S Rudy; C Muir; S Zhai; W D Figg; J A Cook; J B Mitchell; C Van Waes
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

7.  [Recurrent mammary carcinoma after local excision].

Authors:  R Bässler
Journal:  Strahlenther Onkol       Date:  1996-01       Impact factor: 3.621

8.  [Prospective phase II study of neoadjuvant radiochemotherapy in advanced operable carcinoma of the mouth cavity. 3-year outcome].

Authors:  A Eckardt; D Rades; V Rudat; C Hofele; R Dammer; B Dietl; I Wildfang; J H Karstens
Journal:  Mund Kiefer Gesichtschir       Date:  2002-03

9.  Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience.

Authors:  N Zamboglou; T Schnabel; C Kolotas; W Achterrath; H Strehl; S Dalhäuser; H G Vogt; L Lenaz; G Schmitt
Journal:  Semin Oncol       Date:  1994-10       Impact factor: 4.929

10.  In vitro studies of Taxol as a radiation sensitizer in human tumor cells.

Authors:  J Liebmann; J A Cook; J Fisher; D Teague; J B Mitchell
Journal:  J Natl Cancer Inst       Date:  1994-03-16       Impact factor: 13.506

View more
  3 in total

1.  Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy.

Authors:  Oliver Driemel; Tobias Ettl; Oliver Kölbl; Torsten E Reichert; Bernd V Dresp; Jürgen Reuther; Hans Pistner
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

2.  Effect of neoadjuvant chemoradiation and postoperative radiotherapy on expression of heat shock protein 70 (HSP70) in head and neck vessels.

Authors:  Frank Tavassol; Horst Kokemüller; Rüdiger Zimmerer; Nils-Claudius Gellrich; André Eckardt
Journal:  Radiat Oncol       Date:  2011-07-11       Impact factor: 3.481

3.  IMRT in oral cavity cancer.

Authors:  Gabriela Studer; Roger A Zwahlen; Klaus W Graetz; Bernard J Davis; Christoph Glanzmann
Journal:  Radiat Oncol       Date:  2007-04-12       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.